Showing 861-870 of 951 results for "".
- Ketogenic Diet Results in Metabolic Changes in Astrocytomahttps://practicalneurology.com/news/ketogenic-diet-cause-metabolism-changes-in-treated-individuals-with-astrocytomas/2469634/According to a new study published in Neurology, a ketogenic diet may be beneficial for individuals with astrocytomas. Brain scans of 21 of 25 participants who completed the study and followed the di
- Plant-Based Diet Correlates With Reduced Stroke Riskhttps://practicalneurology.com/news/plant-based-diet-correlates-with-reduced-stroke-risk/2469525/A study published in Neurology, showed a correlation between a diet high in quality plant-based foods and up to a 10% reduced risk of ischemic. Compared with people who ate the fewest healthful plant-based foods, people who ate the most had a 10% lower risk of having a stroke. Participa
- Healthy Diet May Reduce Nonmotor Symptoms of Prodromal Parkinson Diseasehttps://practicalneurology.com/news/healthy-diet-may-reduce-nonmotor-symptoms-of-prodromal-parkinson-disease/2469355/A new study published in the August 19, 2020 online issue of Neurology suggests that eating a healthy diet in midlife may be linked to fewer nonmotor symptoms of Parkinson Disease (PD). In this study, participants who strictly followed specific healthy diets were less likely to ha
- Diet High in Fish and Vegetables May Help Preserve Cognitionhttps://practicalneurology.com/news/diet-high-in-fish-and-vegetables-may-help-preserve-cognition/2469228/Results of a study published in Alzheimer (AD) and Dementia show adherence to the Mediterranean diet (high in vegetables, whole grains, fish, and olive oil) correlates with higher cognitive function. Dietary factors also seem to play a role in slowing cognitive decline. Researchers at the Nationa
- Protein Levels in Plasma Highly Predictive of Future Dementia Risk According to UK Biobank Studyhttps://practicalneurology.com/news/protein-levels-in-plasma-highly-predictive-of-future-dementia-risk-according-to-uk-biobank-study/2470405/People with higher baseline plasma levels of certain proteins, including glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), growth/differentiation factor 15 (GDF15), and latent-transforming growth factor beta-binding protein 2 (LTBP2), had an elevated risk of developing deme
- Midlife Plasma Levels of Amyloid Beta May Predict Future Dementia or Mild Cognitive Impairmenthttps://practicalneurology.com/news/midlife-plasma-levels-of-amyloid-beta-may-predict-future-dementia-or-mild-cognitive-impairment/2469658/Data from the Arthritis in Communities study (NCT00005131) published in Neurology showed midlife plasma levels of amyloid beta 42 (Aβ
- Antibody–Oligonucleotide Conjugate Shows Target Engagement in Myotonic Dystrophy Type 1https://practicalneurology.com/news/antibodyoligonucleotide-conjugate-shows-target-engagement-in-myotonic-dystrophy-type/2485921/Treatment with delpacibart etedesiran (del-desiran [AOC 1001]; Avidity Biosciences, San Diego, CA), a monoclonal antibody (mAb) oligonucleotide conjugate, reduced DMPK mRNA levels and demonstrated improvement in downstream splicing biomarkers in adults with myotonic dystrophy type 1 (DM1). These
- Adding Repatha Treatment to Lipid-Lowering Therapy Shown to Reduce Risk of First Major Adverse Cardiovascular Eventshttps://practicalneurology.com/news/adding-repatha-treatment-to-lipid-lowering-therapy-shown-to-reduce-risk-of-first-major-adverse-cardiovascular-events/2484500/The addition of the proprotein convertase subtilisin/Kexin type 9 (PCSK9) enzyme inhibitor Repatha (evolocomab; Amgen, Thousand Oaks, CA) to standard low-density lipoprotein cholesterol (LDL-C)–lowering therapy for people with atherosclerosis or diabetes but no previous myocardial infarction or s
- FDA Grants Breakthrough Therapy Designation to Delpacibart Zotadirsen for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/fda-grants-breakthrough-therapy-designation-to-delpacibart-zotadirsen-for-duchenne-muscular-dystrophy/2475932/Del-zota (delpacibart zotadirsen; Avidity Biosciences, San Diego, CA) has been granted Breakthrough Therapy designation by the Food and Drug Administration (FDA) as an investigational therapy for the treatment of people with Duchenne muscular dystrophy (DMD) with mutations amenable to exon 44 ski
- Draft Guidelines for the Treatment of Infantile Epilepsy Syndromes: Comments Requestedhttps://practicalneurology.com/news/new-guidelines-proposed-for-treatment-of-infantile-epilepsy-syndromes-comments-requested/2475300/The American Epilepsy Society (AES) has released a comprehensive draft clinical practice guideline that provides evidence-based recommendations for the pharmacologic, surgical, and dietary treatment of epilepsy syndromes in infants aged <36 months. The guideline updates a previously published